The use of nitro-vasodilators for achieving rapid uterine relaxation in the resolution of obstetric emergencies has been documented for nearly 120 years. Glyceryltrinitrate (GTN) is the most commonly used nitro-vasodilator for this purpose, with the presumed mechanism of action being via nitric oxide and cyclic guanosine monophosphate (cGMP) mediated processes. GTN is known to release nitric oxide to effect smooth muscle relaxation and some dose response data is available for its vasodilator activity. Human myometrium is known to synthesize and respond to nitric oxide, with changes in the production of and sensitivity to nitric oxide being subject to the cyclical and gestational state of the uterus. Experimental data on the efficacy of GTN in reliably producing uterine relaxation is conflicting and inconsistent. A total of 32 studies and case reports on the use of GTN in achieving rapid uterine relaxation have appeared in the English language literature. Case reports are subject to reporting bias and prospective randomized controlled trials are not without design flaws. Indications for the use of GTN in achieving rapid uterine relaxation cover the antepartum, intrapartum and postpartum periods. The safety of GTN during obstetric emergencies appears high, with no adverse maternal or neonatal outcomes. To establish the efficacy of GTN in reliably achieving uterine relaxation, well designed randomized controlled trials in labouring women are required.
Glyceryl trinitrate (GTN) is a nitro-vasodilator that exerts its effect by releasing nitric oxide (NO). It is thought the smooth muscle relaxation effect of NO is mediated by an increase in intracellular cyclic guanosine monophosphate (GMP). The uterus is a smooth muscle organ and nitro-vasodilators such as amyl nitrate have been used to achieve rapid uterine relaxation for over a century [1] [2] [3] . The use of GTN to achieve rapid uterine relaxation during obstetric emergencies has generated many observational studies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and case reports [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in the anaesthetic and obstetric literature. The ability to achieve simple, reliable and rapid uterine relaxation is of particular interest to the anaesthetist, as this would lessen the need to subject the parturient to the risks of anaesthesia.
The aim of this review is to outline the physiological and pharmacological principles involved in this use of GTN, examine the issues involving in vitro and in vivo scientific research, review all published English language reports of the use of GTN for rapid uterine relaxation, and to assess the safety of GTN in the parturient and fetus.
BACKGROUND
In 1882, Barnes was the first to record the use of a nitro-vasodilator to achieve rapid uterine relaxation. Inhaled amyl nitrite was used for the manual removal of retained placenta behind a cervical contraction ring 1 . A 1928 review of uterine contraction rings and the use of amyl nitrite reported four other cases in addition to that of Barnes 2 . A 1965 prospective observational study of the effects of amyl nitrite demonstrated no effect during spontaneous labour in five parturients, but a definite effect in 10 of 12 parturients with oxytocin induced activity 3 .
Glyceryl trinitrate is commonly used for the treatment of angina pectoris and a number of studies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and case reports [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] suggest it is effective in producing rapid uterine relaxation. The first such report, by Peng in 1989, included 15 patients successfully treated with GTN during the manual removal of retained placenta 16 . Other applications in obstetric practice have included therapeutic cerclage placement 23 , tocolysis for fetal distress 11,21, internal [12] [13] [14] and external 4, 5, 9, 28, 29 versions, entrapped fetuses at vaginal 8, [17] [18] [19] 26, 35 and caesarean delivery 8, 14, 22, 25, 31, 34 and uterine inversion 5, 20, 24, 25, 32, 33 .
The principal mechanism by which GTN is understood to exert its effect is via the release of nitric oxide (NO). The role of NO in the endometrium, myometrium and its role during pregnancy have been well reviewed [36] [37] [38] .
Previous reviews of GTN and uterine relaxation 39, 40 have not systematically reviewed all the data available regarding dosage, indications, timing, or maternal and fetal safety. This paper aims to complete this task. Only two randomized controlled trials have been published 4, 6 and other in vitro and in vivo animal data conflict with respect to the efficacy of GTN in reliably producing rapid uterine relaxation.
PHYSIOLOGY
The uterus is an organ containing a syncytium of smooth muscle that changes its function depending upon the reproductive phase. Of the numerous influences on the contractility of uterine smooth muscle, NO has received most attention. The bulk of the evidence suggests that the myometrium is able to synthesize NO, and that its capacity to synthesize NO and sensitivity to NO is dependant on the reproductive phase.
An in vitro study on human myometrial strips by Lee and Chang compared non-pregnant with pregnant myometrium. They demonstrated that human myometrium contains an L-arginine/NO system and that both pregnant and non-pregnant myometrium relax in response to exogenous NO, although the pregnant myometrium is more sensitive 41 . This may contribute to uterine quiescence during pregnancy 37, 41 .
Various reviews 37, 38 and studies 41, 50 cite evidence for a reduced production of, and sensitivity to, NO within the myometrium during labour when compared to late gestation. Ekerhovd et al have questioned these findings, based on an in vitro study that found no difference in the responsiveness of human myometrial strips to exogenous NO when comparing late gestation and labouring uteri 43 .
As a smooth muscle relaxant, NO is synthesized intracellularly, in nerve cells, endothelial cells, endometrium 36 and probably myometrial cells themselves [41] [42] [43] [44] , by the conversion of L-arginine to L-citrulline, a process catalysed by the enzyme, nitric oxide synthase (NOS) and inhibited by N g -monomethyl-arginine (L-NMMA) and via a negative feedback loop. NO is highly diffusible and able to cross smooth muscle membranes where, as a nitrosothiol intermediary, it binds to the haem moiety of guanylate cyclase, thus activating it. This leads to increased intracellular cyclic guanosine monophosphate (cGMP) 45 . Intracellular increase of cGMP activates protein kinases, resulting in reductions of [Ca ++ ] inside the cell and smooth muscle relaxation 43 (Figure 1 ).
Processes independent of cGMP are also thought to operate in producing myometrial smooth muscle relaxation. Bradley et al demonstrated that NO is able to relax myometrial cells independently of cGMP via activation of Ca ++ dependant K + channels 44 (Figure 1 ).
PHARMACOLOGY OF NITRO-VASODILATORS History
GTN was first synthesized in 1846 and its medicinal use described in the Lancet in 1879. Murrell described its anti-anginal properties in a series of articles 46 , and others have reviewed nitro-vasodilators from a historical perspective [47] [48] [49] . Amyl nitrite was first synthesized in 1859 and used in 1869 48 . However, it was not until the 1930s that systematic attempts were made to synthesize other nitro-vasodilators, culminating in the production of isorbide dinitrate in Sweden and independently in the United States in the 1950s 48 . Sodium nitroprusside was first synthesized in 1850, and used clinically in 1928, but it was not until 1974 that it gained widespread commercial use due to difficulties in its manufacture and concerns over cyanide toxicity 49 .
Understanding of the mechanism of action of nitro-vasodilators took a slower pace. As far as antianginal effects were concerned, coronary vasodilation was thought to be the principal effector until the 1970s 47 . The realisation that nitrates decreased coronary blood flow in response to decreased O 2 demand focussed attention on peripheral dilational effects 47 . By the 1980s it was appreciated that these agents released NO via various means, and that NO interacted with intracellular guanylyl cyclase to increase cGMP and thus effect vascular smooth muscle dilatation 50 . That NO was in fact endothelial derived relaxing factor was realised a few years later 51 .
Pharmacokinetics
A number of reviews have detailed the pharmacokinetics of intravenous (IV) and sublingual (SL) GTN [52] [53] [54] . Arterial concentrations have been noted to be higher than venous concentrations, suggesting a more avid uptake of GTN in veins. This is consistent with observations that GTN has greater veno-dilatory than arterial-dilatory effects 54 . Pharmacokinetic data are summarized in Table 1. A preliminary study by Wei and Reid 55 considered the time course of plasma GTN levels and corresponding haemodynamic parameters following 600 µg SL. Maximal plasma concentrations of 1.4 to 1.6 ng/ml occurred at 2 to 5 minutes. These plasma concentrations correlated with maximal heart rate increases and left ventricular diastolic dimension decreases.
A prospective trial by David et al 6 investigating GTN and fetal extraction at caesarean section also measured maternal venous blood levels following 250 µg and 500 µg IV. Mean plasma concentrations 1 minute after IV administration were 38.137 ng/ml and 80.301 ng/ml respectively.
A large clearance and volume of distribution suggest significant extrahepatic metabolism and high tissue distribution 53 . Hepatic glutathione nitrate reductase is responsible for the metabolism of GTN to water-soluble metabolites, which then undergo renal excretion 52, 54 . Erythrocyte 52 and vascular 54 metabolism are also reported.
Few human studies have addressed placental transfer. David et al 6 measured umbilical venous and arterial GTN levels and found fetal blood levels were far lower than maternal. The maternal/fetal ratios were 400 after 250 µg and 164 after 500 µg of GTN. Umbilical artery/vein ratios were 1:12 and 1:11 respectively. This data suggests that placental transfer is minimal and the fetus has an extensive capacity to distribute and or metabolize maternally administered GTN. 
EXPERIMENTAL DATA ON NITRIC OXIDE DONORS AND UTERINE FUNCTION
Issues confounding research include differences between animal and human tissues; different GTN concentrations in a laboratory water-bath, human arterial and venous plasma and effect sites in myometrium; and different measures of myometrial response (clinical palpation, successful clinical outcome, uterine pressure transduction and tocodynametry).
Animal Research
Rodent [56] [57] [58] [59] [60] and ovine 60,61 models form the basis of laboratory research on the effects of exogenous NO donors on uterine function during gestation. Information from primate research models 62 , for prevention of preterm labour, is of limited application to a review of GTN for acute uterine relaxation.
In a study using rat preterm myometrial strips, Diamond and Marshal 56 developed concentration response curves to GTN and other smooth muscle relaxants. A 42% reduction in action potential frequency and a 47% reduction in tension occurred at a GTN concentration of 6 x 10 -4 M. These reductions were accompanied by reductions in the frequency of pacemaker discharge and in the maximal rate of rise and fall in action potential configuration. In another study these investigators found no correlation between cGMP levels and the uterine relaxant effect of GTN 57 .
Another study compared the in vitro and in vivo effects of a NO donor on rat uteri during late gestation, preterm and term labour 58 . Myometrial strips from labouring rats were relatively non-responsive to the NO donor diethylenetriamine-nitric oxide (DETA/NO). In contrast, the in vivo arm of the study, using intrauterine pressure monitoring, found a pronounced inhibitory effect of DETA/NO on uterine activity that was greater in labouring (both term and pre-term) than non-labouring rats. The hypothesis proposed as an explanation for the conflicting findings was that an intact feto-placental unit may contribute to the action of NO, by an as yet unknown mechanism.
Segal, Csavoy and Datta examined the hypothesis that placental tissue plays a role in the efficacy of GTN in producing uterine relaxation 59 . By adding homogenized placental tissue to the study preparations, they found that pregnant myometrial strips were far more sensitive to the effects of GTN than were strips not exposed to placental tissue. They also compared these myometrial strips to aortic ring smooth muscle. Myometrial strips exposed to placental homogenates and GTN had similar reductions in tension to aortic ring smooth muscle also treated with GTN, but placental tissue did not enhance the effects of GTN on aortic muscle. The concentrations of GTN used ranged from 2 x 10 -9 to 2 x 10 -5 M. A 50% reduction in force in myometrial strips exposed to placental homogenate occurred at a mean GTN concentration of 1 x 10 -5.92 M.
In a combined in vitro (rabbits) and in vivo (rabbits and sheep) study, Langevin et al 60 were unable to demonstrate reductions in tension or uterine intracavity pressure in the presence of GTN at doses sufficient to cause significant haemodynamic changes. The in vivo rabbit model study was performed two hours post partum and thus placental tissue was not present. The labouring ewes had an intact placenta and interspecies difference was offered as an explanation for the conflicting results compared with those of Segal et al 58 . A positive effect of GTN on the myometrium was seen with the rabbit in vitro preparations when compliance, rather than active tension, was measured. A 47% reduction in compliance was noted at GTN concentrations of 1 x 10 -5 M when compared to control. The authors defined active tension as the "force generated by the contractile elements of a muscle" and compliance as "the change in tension with respect to length". They also proffered that most clinical reports on the effectiveness of GTN rely on palpation by the obstetrician to assess effectiveness. In these circumstances, a perceived reduction in tension may not represent uterine relaxation (i.e., a reduction in active tension), but rather a reduction in uterine compliance. The effect of GTN on compliance may be independent of NO and cGMP mediated processes, a hypothesis consistent with the findings of Diamond 57 . If this is the case, this has serious implications for research using NO donors other than GTN when trying to elucidate the effects of GTN on myometrial activity.
Heymann et al 61 measured intra-amniotic pressure in four near-term pregnant ewes in active labour exposed to IV GTN at 1 to 3 µg/kg/min. GTN stopped uterine contractions and the standard deviation of time averaged intra-amniotic pressure fell from 2.65 to 1.2 (P<0.001). Wheeler et al studied pregnant ewes to determine the maternal and fetal haemodynamic effects of nitro-vasodilators 63 . Although not primarily designed to assess the effect of GTN on uterine tone, intrauterine pressures were monitored with indwelling transducers, and no change in intrauterine pressure was noted following infusion of GTN or nitroprusside.
Anaesthesia and Intensive Care, Vol. 29, No. 2, April 2001 In Vitro Human Research Studies on human myometrial strips obtained at elective caesarean section confirm that GTN abolishes spontaneous contractions 8, 64, 65 . Axemo et al 8 reported that water bath concentrations of GTN at 10 to 25 µg/ml reduced both spontaneous and oxytocin enhanced contractions to between 20% and 70% of control. In the in vivo clinical observation arm of their study, they administered 100 to 200 µg of IV GTN, which based on the data of Wei and Reid 55 , would result in plasma concentrations of less than 1.4 to 1.6 ng/ml. Shin et al 64 reported that mean water-bath concentrations of GTN at 4.5 x 10 -4 M (0.1021 µg/ml) abolish spontaneous contractions of in vitro myometrial strips. No conclusions were drawn about the clinical applications of these findings. Norman et al 65 reported that similar concentrations (10 -4 M) produced a 40% reduction in the amplitude of spontaneous contractions. They commented that such in vivo plasma concentrations would result in profound haemodynamic derangement, although, of course, venous plasma is not the effect site of GTN.
CASE REVIEWS
Since Peng's original report in 1989 16, there have been a total of 13 studies or case series [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and 19 case reports [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , amounting to 346 (324 and 22 respectively) patients reported in the English language literature who received GTN for rapid uterine relaxation, either for obstetric emergencies or for the assessment of GTN effect. For a full summary of all reports see Table 2 .
Of the 13 studies, two are prospective, randomized, placebo-controlled double-blind trials assessing the effectiveness of GTN in producing uterine relaxation 4,6 . Neither found a statistically significant difference between GTN and placebo. Eleven studies are either prospective observational studies or retrospective chart reviews.
Yanny et al 4 recruited 57 patients undergoing external cephalic version. Thirty-one patients were randomized to SL GTN 800 µg and 26 patients to placebo. In the GTN group, 9 of 31 patients had successful external version compared with 3 of 26 in the placebo group. Although not statistically significant, the authors were of the opinion this was clinically significant. In order for a significant difference to have been found at the observed proportions of success, a study of 122 patients would have been required.
David et al 6 enrolled 97 patients in their study on the effects of IV GTN on uterine tone during caesarean section under inhalational general anaesthesia. A placebo group of 31 patients was compared with 32 patients receiving 250 µg and 34 patients receiving 500 µg of GTN. Assessment of uterine tone was by subjective palpation by the attending obstetrician according to a four-point scale, and ease of fetal extraction was assessed using a three-point scale. Thirty-nine obstetricians took part in the assessment of the 96 patients and the placebo and two treatment groups were similar. The only significant difference was a greater reduction in systolic and diastolic blood pressure after 500 µg compared with 250 µg or placebo. Maternal and fetal pharmacological data were also collected, as outlined earlier in this paper under Pharmacokinetics.
Clinical applications of GTN have extended from the antepartum (cervical cerclage, uterine hyperstimulation, external version) through the intrapartum (difficult extractions and elective caesarean section) to the postpartum period (uterine inversion and retained placenta) ( Table 3) . Two publications by one group of authors 12, 13 may have analysed the same patient base, so figures in parentheses exclude this potential double counting.
In two studies, a total of 89 patients received GTN during elective caesarean section as a means of achieving uterine relaxation 6, 7 . Maternal and fetal effects were also evaluated. Craig et al 7 claimed an effect of GTN on uterine tone demonstrated by use of a subjective ten-point scale with the patients acting as their own control. Subjective scores were given on uterine incision (median score 3-low tone, GTN effect) and on uterine closure (median score 8-high tone, GTN worn off) and no comment was made on the statistical significance of these results.
The dosage of GTN used in published reports varies from 50 µg to 1850 µg. Generally IV GTN 100 µg to 500 µg and SL GTN (74 patients) 400 µg to 800 µg (1-2 metered sprays) was administered.
The timing of GTN effect was not reported in seven of the 32 reports, but in general, after both IV and SL administration, a relaxed uterus was observed within 90 seconds. Time to spontaneous return of normal uterine tone was recorded in four reports 14, 15, 19, 26 , and was usually within a few minutes, the maximum being six minutes.
The use of GTN did not apparently affect the sensitivity of the uterus to uterotonic agents. One report cited the alternating use of GTN and syntocinon 27 . The uterus relaxed with GTN after a dose of syntocinon, and then responded to a repeat dose of syntocinon. The diagnosis of placenta accreta was then made and the placenta left in situ for spontaneous resorption.
Assessment of the effect of GTN on uterine tone is problematic in almost all reports. Uterine activity measured by an intrauterine pressure catheter is considered the "gold standard" 66, 67 . The accuracy of such catheters has been confirmed in both second 68 and third stage labour 69 . Arrabel and Nagey 70 found that assessment of activity by palpation of the uterus, by obstetricians, senior trainees, residents and midwives was accurate only 48% of the time when compared with intrauterine pressure monitoring. Only two reports used intrauterine pressure measurements to assess GTN effect 21, 30 . Ley et al 30 configured an intrauterine pressure transducer from a 7.0 mm internal diameter endotracheal tube, with the cuff partially inflated with saline, and the cuff port connected to a transducer system. Although the intrauterine pressure fell from 38 mmHg to 23 mmHg following 500 µg of GTN, their catheter system has not undergone the rigorous validation process of new catheters, as described by Dowdle 71 . The case report by Bell 21 includes a copy of the tocodynamometer strip, with annotations indicating the timing of GTN administration (800 µg SL). A definite change in the tracing lasting six minutes is apparent. All other reports relied on palpation by the obstetrician or the ability to effect the desired outcome (i.e., extract the fetus or placenta, perform version, re-invert the uterus) as an indication of uterine relaxation. Of the 346 patients described, only 97 were compared to placebo controls to validate the apparent effectiveness of GTN.
SAFETY ASPECTS OF GTN ADMINISTRATION Information from Case Reviews
Haemodynamic compromise is one of the major concerns regarding the safety of GTN in obstetrics. In 48 patients clinically significant reductions in blood pressure (the criteria being a greater than 20% fall in systolic blood pressure or the requirement of intervention) were documented. No patients experienced adverse sequelae as a consequence of this.
Other safety parameters of concern include postpartum haemorrhage and atonic uterus. There were nine cases in which associated blood loss exceeded 500 ml, but no blood transfusions. One report described uterine atony and subsequent uterine inversion during caesarean section 22 . The administration of GTN to facilitate the difficult extraction of a macrosomic fetal head was thought to have contributed. The patient was not compromised, and uterotonics (methylergonovine and a prostaglandin F 2α analogue) corrected atony within five minutes.
Other maternal side-effects reported after GTN included flushing (eight patients), headache (eight patients), light-headedness (two patients) and nausea and vomiting (two patients). The incidence of these side-effects cannot be assessed as maternal symptoms were not always detailed and symptoms may have been masked by general anaesthesia.
Neonatal assessment was incorporated into all relevant reports. There were no low five-minute Apgar scores and the two placebo controlled studies 4, 6 reported no difference in Apgar scores between placebo and GTN groups.
Other Studies and Reports
Haemodynamic and uteroplacental flow after maternal GTN have been investigated in sheep 63, 72, 73 . After examining the effects of infused GTN in the presence and absence of noradrenaline, the authors suggested that GTN could be considered as an antihypertensive drug for preeclampsia.
Wheeler et al 63 infused GTN to a rate at which mean arterial pressure (MAP) fell 15 to 25%. During this infusion phase other changes were in pulse rate 23 1 Uterine hyperstimulation/fetal distress 11, 21 25 External version 4, 5, 9, 28, 29 45 Internal version [12] [13] [14] 21 (12) 8, 17, 18, 19, 26, 35 14 (caesarean delivery) 5, 8, 14, 22, 25, 31, 34 41 Postpartum
Retained placenta 5, 8, 10, 14, 15, 16, 25, 27, 30 104 Uterine inversion (vaginal delivery) 5, 20, 24, 25, 33 5 (caesarean delivery) 32 1
The numbers in brackets excludes the potential for double counting in two reports where the patient base may overlap.
(33% increase), uterine blood flow (7% fall), and uterine conductance (4.6% rise). De Rosayro et al 72 measured haemodynamic and metabolic parameters in both the pregnant ewe and fetus following GTN infusion to a rate at which maternal MAP fell by 30%. This was not accompanied by a significant rise in heart rate (17%), but uterine flow fell 42%. Maternal PaO 2 also fell from 108 mmHg to 87 mmHg (19% decrease), but maternal pH, PCO 2 and base excess were unchanged. Fetal haemodynamic and biochemical parameters did not change significantly and the maternal to fetal arterial GTN ratio was 25.
During maternal infusions of GTN in sheep, Bootstaylor et al 73 measured maternal arterial pressure (15% fall) and heart rate (11.5% rise), umbilical flow (no change), mean amniotic pressure (no change), umbilical O 2 and substrate uptake (glucose and lactate-no change), and maternal and fetal blood gases and haemoglobin (no change). Using radioactive microsphere analysis of fetal blood flow distribution, a trend toward flow reduction to non-vital organs (musculo-skeletal system, gastrointestinal tract, liver, kidney and spleen) with a concomitant increase in flow to heart and brain was noted. As GTN was infused in increasing doses over a total of two hours, the trend was not thought to be clinically relevant to use of GTN in a single dose or as a brief infusion for uterine relaxation.
A clinical study by Cacciatore et al 74 investigated GTN in pre-eclamptic women in whom there was evidence of compromised uteroplacental flow. To prevent preterm labour, transdermal GTN 10 mg per 24 hours was given to 17 pre-term pre-eclamptic women for three consecutive days. As assessed by ultrasonography, uterine artery pulsatility and resistance indices fell (18% and 17% respectively) but here were no changes in umbilical or fetal middle cerebral artery pulsatility and resistance indices.
CONCLUSION
The evidence supporting the acute administration of GTN in producing uterine relaxation to assist in the resolution of obstetric emergencies is inconsistent. The traditionally held view that GTN releases NO, with subsequent effects of NO on uterine smooth muscle acting via a cGMP mediated process in effecting uterine relaxation, is not borne out by all laboratory work. No correlation was found between cGMP and uterine relaxant effects of GTN 57 . In vitro studies using myometrial strips, whether rodent, ovine or human, have found relaxant effects of GTN at concentrations that are not clinically relevant based on available pharmacokinetic and pharmacodynamic data. In vivo animal models also conflict: studies showing no effect of GTN in rabbits 60 , no change in intrauterine pressure but a reduction in uterine compliance with GTN in sheep 60 , no effect of GTN in pregnant sheep 63 , cessation of active labour in sheep in response to GTN 61 and cessation of uterine contractions and reduction in intrauterine pressures secondary to GTN administration in the rhesus monkey 62 .
There are several potential reasons for these conflicting results, with inter-species differences being a likely cause. In addition, the uterine response to NO differs throughout various stages of the reproductive cycle and studies have examined preterm, near-term and labouring uteri in various animal and human models, both in vitro and in vivo. Some studies included placental tissue, which may play a role in enhancing the uterine response to GTN.
The strongest evidence that GTN reliably produces rapid uterine relaxation comes from the large number of clinical reports detailing 346 patients. However, case studies and case series predominate and many of the studies are retrospective, uncontrolled or subject to reporting bias. The two randomized controlled trials, both of which found no effect of GTN, also contain methodological flaws. The study by Yanny et al 4 may have been, by the authors' admission, of insufficient size to find a statistically significant difference between GTN and control groups. David et al 6 used a large randomized controlled study design, but assessments of uterine tone were made by 39 different obstetricians using manual palpation, a method that is known to be inaccurate 70 . In addition, patients had undergone general anaesthesia and these drugs may have altered uterine tone. Confounding factors such as these make it impossible to draw meaningful conclusions.
Assessment of uterine tone by manual palpation is problematic. Langevin et al 60 have suggested that changes in uterine compliance are perceived by manual palpation and that this is not recorded by intrauterine pressure monitoring. In contrast, the report by Bell 21 clearly demonstrated a change in the intra-uterine transducer tracing chronologically related to GTN administration. Two other animal reports also indicate intrauterine pressure monitoring is an objective measure of the myometrial effects of GTN 61, 62 .
Despite these reservations, a large number of reports attest to the ability of GTN to provide uterine relaxation, although evidence is lacking that GTN affects the uterus in a reliable and reproducible manner. Adequate dose-response data for GTN and relaxation of uterine tone are also lacking.
The safety of GTN in the peri-partum period has been adequately established. Maternal hypotension is well documented, although the incidence is difficult to estimate and dose response data are not available. Where hypotension occurred, it did not result in any adverse maternal or neonatal sequelae. In the potentially haemodynamically compromised mother, the haemodynamic effect of alternatives such as inhalational anaesthesia, magnesium sulphate and beta-sympathomimetics must be considered and are not without risk. The rapidity of onset and offset that GTN provides appears a distinct advantage.
A strength of the two randomized controlled studies is their observation of a good neonatal outcome after GTN. No adverse sequelae were found for uterine, umbilical and fetal flow patterns, or in fetal metabolic parameters in both animal 63, 72, 73 and human studies 74 . The reports of maternal pulmonary oedema in association with GTN 75, 76 have little relevance to the clinical settings covered in this review, namely the use of GTN in achieving rapid uterine relaxation to assist in resolving obstetric emergencies. The patients in these reports received prolonged tocolytic therapy following fetal surgery and GTN was not always administered in isolation.
The administration of GTN for uterine relaxation is not universally accepted practice amongst obstetric anaesthetists. A survey at the 1993 meeting of the Society for Obstetric Anesthesia and Perinatology found that only 39.2% of respondents would use GTN for acute intrapartum tocolysis. General anaesthesia with intubation and halogenated agent was used by 27.4% of respondents, and 16% would use betasympathomimetics 77 .
In order for GTN to achieve widespread use in obstetric emergencies, a better understanding of the mechanisms of GTN and NO as they pertain to the human myometrium at the appropriate gestational stages is required. Well conducted randomized controlled trials in the obstetric emergency setting, where GTN seems to have a distinct advantage in speed of onset, may be difficult to conduct. A randomized controlled trial conducted in the nonemergency setting would require sufficient numbers of labouring women with intrauterine pressure transducers to monitor the potential effects of GTN and placebo. Until such trials are performed, clinicians seeking potentially life-saving management options are faced with reliance on clinical reports, in the presence of conflicting clinical and experimental data.
